Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws

Table 1 Patients and Bisphosphonate Therapy Characteristics

Authors/Study	Gender	Age	Comorbidities	Medications (Years)
Marunick et al. [4] CS Patient 1	F	59	OST	STE + METX + AL (3)
Yarom et al. [6] RS
Patient 2	F	73	HTN	STE + METX + AL (7), infliximab
Patient 3	F	76	HTN + Arrhythmia + hypercholesterolemia	AL (1.5)
Malden & Pai [7] CS Patient 4	F	56	NO	STE + AL (1), leflunomide
Khamaisi et al. [8] RS Patient 5	F	73	DM	AL (> 0,5)
Marx et al. [9] CS
Patient6	F	NA	OST	STE + METX + AL (3.1)
Patient 7	F	NA	OST	STE + METX + AL (6.3)
Patient 8	F	NA	OST	STE + METX + AL (3.3)
Hamada [10] CR
Patient 9	F	68	OST	STE + RISE (4)
Barrow [11] CR
Patient 10	F	70	OST	STE + AL (< 3)
Junquera et al. [12] CS
Patient 12a/12b	M	73	NO	STE + METX + AL (3.8)
Mehanna et al. [13] CR
Patient 13	F	55	NO	STE + Leflunomide + oral BPs (1)
Favia et al. [14] CS
Patient 14a/14b	F	67	OST	STE + IBAN (1)
Kwon et al. [15] CR
Patient 15	F	71	OST + DM	STE + AL (3); OH
Sedghizadeh et al. [16] RS
Patient 16	F	63	OST + HTN	STE + chemotherapy + AL (3)
Lo et al. [17] RS
Patient 17	NA	NA	NO	oral BPs (4.8)
Patient 18	NA	NA	Hip Osteonecrosis	STE + oral BPs (2.6)
Shin et al. [18] CR
Patient 19	F	67	OST + HTN	AL (1) + HTN Drug
Park et al. [19] CS
Patient 20	F	68	OST	STE + AL (5)
Patient 21	F	69	OST + PLE + TB	STE + AL (10)
Patient 22	F	70	OST + HTN	STE + AL (6)
Manfredi et al. [20] CS
Patient 23	F	68	OST + DM + HTN	AL (4.25)
Patient 24	F	65	OST + HTN	AL (5)
Patient 25	F	79	OST	AL (4)
Patient 26	F	57	OST + DM + HTN	AL (> 3)
Conte-Neto et al. [21] CR
Patient 27	F	58	NO	AL (5)
Patient 28	F	68	OST	STE + METX + AL (7)

CS Case series, RS Retrospective study, CR Case report, NA Not available
OST Osteoporosis, HTN Hypertension, DM, Diabetes Mellitus, GU gastric ulcer, PLE Pleuritis, TB Tuberculosis, STE Steroids, MTX Methotrexate; AL Alendronate, RISE Risedronate, IBAN Ibandronate, OH oral hypoglycemiant